Hipp, S
Tai, Y-T
Blanset, D
Deegen, P
Wahl, J
Thomas, O
Rattel, B
Adam, P J
Anderson, K C
Friedrich, M
Article History
Received: 28 July 2016
Revised: 28 October 2016
Accepted: 2 December 2016
First Online: 27 December 2016
Competing interests
: SH, PJA and DB are employees of Boehringer Ingelheim. PD, JW, OT, BR and MF are Amgen employees and have received stock. KA serves on advisory boards to Takeda, Celgene, Gilead, and is a scientific founder of Acetylon, Oncopep and C4 Therapeutics. The remaining author declares no conflict of interest.